JP2017530356A - 心血管系のリスクイベントの予測及びその使用 - Google Patents

心血管系のリスクイベントの予測及びその使用 Download PDF

Info

Publication number
JP2017530356A
JP2017530356A JP2017516046A JP2017516046A JP2017530356A JP 2017530356 A JP2017530356 A JP 2017530356A JP 2017516046 A JP2017516046 A JP 2017516046A JP 2017516046 A JP2017516046 A JP 2017516046A JP 2017530356 A JP2017530356 A JP 2017530356A
Authority
JP
Japan
Prior art keywords
risk
biomarker
event
gdf11
individual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017516046A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017530356A5 (enExample
Inventor
デイヴィッド スターリング
デイヴィッド スターリング
シンタロウ カトウ
シンタロウ カトウ
エドワード エヌ． ブロディ
エドワード エヌ． ブロディ
スティーヴン エー． ウィリアムズ
スティーヴン エー． ウィリアムズ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Somalogic Inc
Original Assignee
Somalogic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Somalogic Inc filed Critical Somalogic Inc
Publication of JP2017530356A publication Critical patent/JP2017530356A/ja
Publication of JP2017530356A5 publication Critical patent/JP2017530356A5/ja
Priority to JP2019140401A priority Critical patent/JP6956762B2/ja
Priority to JP2021163792A priority patent/JP7270696B2/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N7/00—Computing arrangements based on specific mathematical models
    • G06N7/01—Probabilistic graphical models, e.g. probabilistic networks
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q40/00—Finance; Insurance; Tax strategies; Processing of corporate or income taxes
    • G06Q40/08—Insurance
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/10—Signal processing, e.g. from mass spectrometry [MS] or from PCR
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/30—Unsupervised data analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
    • C12Q2525/10—Modifications characterised by
    • C12Q2525/205—Aptamer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4712—Muscle proteins, e.g. myosin, actin, protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/515—Angiogenesic factors; Angiogenin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
    • G01N2333/8121—Serpins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Theoretical Computer Science (AREA)
  • Data Mining & Analysis (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Epidemiology (AREA)
  • Databases & Information Systems (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Business, Economics & Management (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Software Systems (AREA)
  • Artificial Intelligence (AREA)
  • Evolutionary Computation (AREA)
  • Bioethics (AREA)
  • Computer Vision & Pattern Recognition (AREA)
JP2017516046A 2014-09-26 2014-11-03 心血管系のリスクイベントの予測及びその使用 Pending JP2017530356A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2019140401A JP6956762B2 (ja) 2014-09-26 2019-07-31 心血管系のリスクイベントの予測及びその使用
JP2021163792A JP7270696B2 (ja) 2014-09-26 2021-10-05 心血管系のリスクイベントの予測及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462055984P 2014-09-26 2014-09-26
US62/055,984 2014-09-26
PCT/US2014/063714 WO2016048388A1 (en) 2014-09-26 2014-11-03 Cardiovascular risk event prediction and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019140401A Division JP6956762B2 (ja) 2014-09-26 2019-07-31 心血管系のリスクイベントの予測及びその使用

Publications (2)

Publication Number Publication Date
JP2017530356A true JP2017530356A (ja) 2017-10-12
JP2017530356A5 JP2017530356A5 (enExample) 2017-12-07

Family

ID=51982763

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017516046A Pending JP2017530356A (ja) 2014-09-26 2014-11-03 心血管系のリスクイベントの予測及びその使用
JP2019140401A Active JP6956762B2 (ja) 2014-09-26 2019-07-31 心血管系のリスクイベントの予測及びその使用
JP2021163792A Active JP7270696B2 (ja) 2014-09-26 2021-10-05 心血管系のリスクイベントの予測及びその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019140401A Active JP6956762B2 (ja) 2014-09-26 2019-07-31 心血管系のリスクイベントの予測及びその使用
JP2021163792A Active JP7270696B2 (ja) 2014-09-26 2021-10-05 心血管系のリスクイベントの予測及びその使用

Country Status (9)

Country Link
US (2) US10670611B2 (enExample)
EP (1) EP3198023B1 (enExample)
JP (3) JP2017530356A (enExample)
KR (1) KR102328327B1 (enExample)
AU (1) AU2014407088B2 (enExample)
BR (1) BR112017005730B1 (enExample)
CA (2) CA2961340C (enExample)
ES (1) ES2792227T3 (enExample)
WO (1) WO2016048388A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021507216A (ja) * 2017-12-13 2021-02-22 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 脳卒中の予測のための循環アンジオポエチン−２（Ａｎｇ−２）およびインスリン様増殖因子結合タンパク質７（ＩＧＦＢＰ７）
JP2022546515A (ja) * 2019-09-03 2022-11-04 ソマロジック オペレーティング カンパニー インコーポレイテッド 心血管リスク／イベントの予測及びその使用
JP2023502984A (ja) * 2019-11-15 2023-01-26 ゲイシンガー クリニック ヘルスケア集団の管理に対する機械学習手法のためのシステムおよび方法
JP2023546563A (ja) * 2020-10-20 2023-11-06 ソマロジック オペレーティング カンパニー インコーポレイテッド 心血管イベントリスクの予測
JP2024525146A (ja) * 2021-06-15 2024-07-10 ソマロジック オペレーティング カンパニー インコーポレイテッド 腎不全の予測及びその使用

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080228700A1 (en) 2007-03-16 2008-09-18 Expanse Networks, Inc. Attribute Combination Discovery
US8108406B2 (en) 2008-12-30 2012-01-31 Expanse Networks, Inc. Pangenetic web user behavior prediction system
WO2010077336A1 (en) 2008-12-31 2010-07-08 23Andme, Inc. Finding relatives in a database
WO2015156125A1 (ja) * 2014-04-11 2015-10-15 株式会社 日立メディコ 医用画像撮影装置及び医用画像撮影方法
CN118522390A (zh) * 2016-04-01 2024-08-20 20/20基因系统股份有限公司 帮助区别良性和恶性放射线照相明显肺结节的方法和组合物
WO2017214684A1 (en) * 2016-06-17 2017-12-21 Adelaide Research & Innovation Pty Ltd Methods and products for identifying conditions associated with cardiac fibrotic remodelling
KR102322258B1 (ko) 2017-05-19 2021-11-04 현대자동차 주식회사 마이크로폰 및 그 제조 방법
US11079394B2 (en) * 2017-07-25 2021-08-03 Vanderbilt University Detection of angiopoietin-2 and thrombospondin-2 in connection with diagnosing acute heart failure
WO2019074491A1 (en) * 2017-10-10 2019-04-18 Flagship Biosciences, Inc. PATIENT STRATIFICATION METHOD USING IMAGE ANALYSIS PARAMETER DELIVERY FUNCTIONS
US10503970B1 (en) 2017-12-11 2019-12-10 State Farm Mutual Automobile Insurance Company Method and system for identifying biometric characteristics using machine learning techniques
US10825564B1 (en) 2017-12-11 2020-11-03 State Farm Mutual Automobile Insurance Company Biometric characteristic application using audio/video analysis
US11317872B2 (en) * 2017-12-15 2022-05-03 Mayo Foundation For Medical Education And Research Predicting transient ischemic events using ECG data
US20190295727A1 (en) * 2018-03-23 2019-09-26 American Heart Association, Inc. System and Method for Assessing Heart Health and Communicating the Assessment to a Patient
EP3922640B1 (en) * 2019-02-08 2023-11-08 NEC Corporation Method for diagnosing human t-cell leukemia virus type 1 (htlv-1) associated diseases
TWI716827B (zh) * 2019-03-06 2021-01-21 國立清華大學 檢測心血管疾病的檢驗套組及心血管疾病相關生物標記的濃度檢測方法
TWI741915B (zh) * 2019-03-06 2021-10-01 國立清華大學 檢測心血管疾病的檢驗套組及心血管疾病相關生物標記的濃度檢測方法
TWI741914B (zh) * 2019-03-06 2021-10-01 國立清華大學 檢測心血管疾病的檢驗套組及心血管疾病相關生物標記的濃度檢測方法
CN110068676A (zh) * 2019-03-22 2019-07-30 同济大学 分泌蛋白Serpin A3在预测心肌损伤诊断试剂中的应用
JP7215682B2 (ja) * 2019-09-09 2023-01-31 ａｉｗｅｌｌ株式会社 情報処理システムおよびプログラム
CN110838339B (zh) * 2019-09-23 2023-05-05 广东工业大学 邻苯二甲酸酯对斑马鱼毒性效应的预测方法、设备及介质
WO2021070649A1 (ja) * 2019-10-10 2021-04-15 ソニー株式会社 表示制御装置、表示制御方法、及び、プログラム
CN115698721A (zh) * 2020-03-18 2023-02-03 豪夫迈·罗氏有限公司 用于卒中的评估的ret（转染重排）
US10902955B1 (en) * 2020-05-01 2021-01-26 Georgetown University Detecting COVID-19 using surrogates
WO2021243166A2 (en) * 2020-05-28 2021-12-02 The Regents Of The University Of Michigan Deterimining risk of spontaneous coronary artery dissection and myocardial infarction and systems and methods of use thereof
US11416776B2 (en) * 2020-08-24 2022-08-16 Kpn Innovations, Llc. Method of and system for identifying and enumerating cross-body degradations
EP4057010A3 (en) * 2021-03-08 2023-01-18 Sanofi Cardiovascular disease
WO2023086746A1 (en) * 2021-11-11 2023-05-19 Beckman Coulter, Inc. Assessment of risk for major adverse cardiac event
CN114445445B (zh) * 2022-04-08 2022-07-01 广东欧谱曼迪科技有限公司 Ct图像的动脉分割方法、装置、电子设备及存储介质
CN117594131B (zh) * 2024-01-17 2024-04-16 北京市心肺血管疾病研究所 用于鉴别或辅助鉴别急性胸痛类型的装置及其应用
WO2025230312A1 (ko) * 2024-04-30 2025-11-06 주식회사 메디웨일 전신질환 위험도 기반 대상체 맞춤형 처방 지원 방법 및 장치
CN118152994B (zh) * 2024-05-11 2024-07-16 四川开物信息技术有限公司 一种安全因素影响计算方法
CN119517393A (zh) * 2024-10-29 2025-02-25 中国疾病预防控制中心慢性非传染性疾病预防控制中心 脑卒中发病风险评估方法及系统

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110144914A1 (en) * 2009-12-09 2011-06-16 Doug Harrington Biomarker assay for diagnosis and classification of cardiovascular disease
WO2013049674A1 (en) * 2011-09-30 2013-04-04 Somalogic, Inc. Cardiovascular risk event prediction and uses thereof

Family Cites Families (248)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4642284A (en) 1983-06-13 1987-02-10 Scripps Clinic And Research Foundation Method and system for detection of complement pathway activation
JPS60192263A (ja) 1984-03-13 1985-09-30 Teijin Ltd 免疫複合体測定用標準物質及びそれを用いた免疫複合体の測定法
US5582862A (en) 1988-04-04 1996-12-10 General Hospital Corporation Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin
US6287793B1 (en) 1988-08-19 2001-09-11 Elan Pharmaceuticals, Inc. Diagnostic methods for alzheimer's disease
US5580737A (en) 1990-06-11 1996-12-03 Nexstar Pharmaceuticals, Inc. High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
US5763177A (en) 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5705337A (en) 1990-06-11 1998-01-06 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-SELEX
US6001577A (en) 1998-06-08 1999-12-14 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
ES2259800T3 (es) 1990-06-11 2006-10-16 Gilead Sciences, Inc. Procedimientos de uso de ligandos de acido nucleico.
AT398004B (de) 1992-04-14 1994-08-25 Berbi Gmbh Verfahren zur bestimmung von plasmin-alpha2- antiplasmin-komplexen unter verwendung eines komplexspezifischen monoklonalen antikörpers
EP0574599A1 (en) 1992-06-13 1993-12-22 BEHRINGWERKE Aktiengesellschaft Process for the detection of complexed cathepsin G and alpha-1-antichymotrypsin
AU689777B2 (en) 1993-05-17 1998-04-09 Fortron Bioscience, Inc. Assay for cardiac troponin I
US6458539B1 (en) 1993-09-17 2002-10-01 Somalogic, Inc. Photoselection of nucleic acid ligands
US5599677A (en) 1993-12-29 1997-02-04 Abbott Laboratories Immunoassays for prostate specific antigen
EP1574577A3 (en) 1994-07-08 2006-06-14 The Johns Hopkins University School Of Medicine Growth differentiation factor-11
US5814464A (en) 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
FR2729759A1 (fr) 1995-01-19 1996-07-26 Pasteur Sanofi Diagnostics Procede de dosage ultrasensible de la troponine i cardiaque
JP4122056B2 (ja) 1995-04-06 2008-07-23 リジエネロン ファーマシューティカルズ，インコーポレイテッド Ｔｉｅ−２リガンド、その作製方法および使用方法
US5795725A (en) 1995-04-18 1998-08-18 Biosite Diagnostics Incorporated Methods for the assay of troponin I and T and selection of antibodies for use in immunoassays
US6627404B1 (en) 1995-04-18 2003-09-30 Biosite, Inc. Methods for improving the recovery of troponin I and T in membranes, filters and vessels
DE69633780T3 (de) 1995-04-18 2011-05-05 Biosite Incorporated, San Diego Verfahren zum assay von troponin i und t und komplexen von troponin i und t und auswahl von antikörpern zur verwendung in immunoassays
US6991907B1 (en) 1995-04-18 2006-01-31 Biosite, Inc. Methods for the assay of troponin I and T and complexes of troponin I and T and selection of antibodies for use in immunoassays
FI104857B (fi) 1996-01-15 2000-04-14 Hytest Oy Sydänlihaksen soluvaurioiden asteen mittaus immunokemiallisella menetelmällä sisältäen menetelmään soveliaat vasta-aineet
WO1997049994A1 (en) 1996-06-25 1997-12-31 Oy Aboatech Ab Method and kit for the diagnosis of troponin i
US7285418B2 (en) 1996-06-25 2007-10-23 Hytest Ltd. Method and kit for the diagnosis of troponin I
US6265564B1 (en) 1996-08-02 2001-07-24 Regeneron Pharmaceuticals, Inc. Expressed ligand-vascular intercellular signalling molecule
US6156521A (en) 1997-12-19 2000-12-05 Biosite Diagnostics, Inc. Methods for the recovery and measurement of troponin complexes
WO1998029726A2 (en) 1996-12-27 1998-07-09 Coulter International Corp. Method of detecting and determining the concentration of total troponin i in a biological sample
EP0983509B1 (en) 1997-05-14 2005-08-17 Biosite Diagnostics Inc. Rapid evaluation of the ratio of biological molecules
US7384751B1 (en) 1997-07-16 2008-06-10 Queen's University At Kingston Methods of diagnosing muscle damage
US6242246B1 (en) 1997-12-15 2001-06-05 Somalogic, Inc. Nucleic acid ligand diagnostic Biochip
AU6117099A (en) 1998-10-21 2000-05-08 Spectral Diagnostics Inc. Cardiac troponin i polypeptide fragments and uses in diagnostics
US20020110523A1 (en) 1999-03-23 2002-08-15 Cornelis Kluft Methods for screening or monitoring the risk of cardiovascular disease relating to sex steroid compound or composition intake and methods for screening sex steroid compound
US20030077668A1 (en) 1999-07-22 2003-04-24 Ikagaku Co., Ltd. Method for arteriosclerosis diagnosis
US7618782B1 (en) 1999-10-18 2009-11-17 Queen's University At Kingston Methods of diagnosing muscle damage
US20050272055A1 (en) 2000-02-01 2005-12-08 Rina Das Method of treating lethal shock induced by toxic agents and diagnosing exposure to toxic agents by measuring distinct pattern in the levels of expression of specific genes
US20030040505A1 (en) 2000-03-31 2003-02-27 The Regents Of The University Of California Synthetic phospholipids to ameliorate atherosclerosis and other inflammatory conditions
AUPR005600A0 (en) 2000-09-12 2000-10-05 University Of Sydney, The Diagnostic assay
US7312325B2 (en) 2000-09-26 2007-12-25 Duke University RNA aptamers and methods for identifying the same
WO2002063302A1 (en) 2001-02-07 2002-08-15 Immunomatrix Inc. A method for reducing heparin interference in diagnostic tests for cardiac troponin
US20040253637A1 (en) 2001-04-13 2004-12-16 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
US20040203083A1 (en) 2001-04-13 2004-10-14 Biosite, Inc. Use of thrombus precursor protein and monocyte chemoattractant protein as diagnostic and prognostic indicators in vascular diseases
US7632647B2 (en) 2001-04-13 2009-12-15 Biosite Incorporated Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes
US7524635B2 (en) 2003-04-17 2009-04-28 Biosite Incorporated Methods and compositions for measuring natriuretic peptides and uses thereof
US20030199000A1 (en) 2001-08-20 2003-10-23 Valkirs Gunars E. Diagnostic markers of stroke and cerebral injury and methods of use thereof
US7713705B2 (en) 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
EP1322957B1 (en) 2001-05-04 2009-08-12 Biosite Incorporated Diagnostic markers of acute coronary syndromes and methods of use thereof
US20020197741A1 (en) 2001-05-11 2002-12-26 Sabucedo Albert J. Method of determining time of death
DK2070939T3 (da) 2001-05-25 2014-06-23 Univ Duke Modulatorer af farmakologiske midler
US20050026165A1 (en) 2001-05-31 2005-02-03 Cindy Orser Detection of conformationally altered proteins and prions
US20030003503A1 (en) 2001-06-29 2003-01-02 Tsai Tenlin S. Enhancing sensitivity and equimolar detection through modifications of the reaction environment
WO2003005890A2 (en) 2001-07-09 2003-01-23 Arizona Board Of Regents A Body Corporate Acting On Behalf Of Arizona State University Affinity biosensor for monitoring of biological process
US7608406B2 (en) 2001-08-20 2009-10-27 Biosite, Inc. Diagnostic markers of stroke and cerebral injury and methods of use thereof
US6461828B1 (en) 2001-09-04 2002-10-08 Syn X Pharma Conjunctive analysis of biological marker expression for diagnosing organ failure
CN100593721C (zh) 2001-11-27 2010-03-10 迪尔基因国际有限公司 用于病人的样本中生物化学标记物的早期和同步检测的免疫测定法和试剂盒
WO2003062824A1 (en) 2002-01-23 2003-07-31 Boditech Inc. Lateral flow quantitative assay method and strip and laser-induced fluoerescence detection device therefor
DE10211818B4 (de) 2002-03-16 2006-07-06 peS Gesellschaft für medizinische Diagnose-Systeme mbH Verfahren zur quantitativen Bestimmung mehrerer Analyten
US6930085B2 (en) 2002-04-05 2005-08-16 The Regents Of The University Of California G-type peptides to ameliorate atherosclerosis
US7939641B2 (en) 2002-04-09 2011-05-10 The Scripps Research Institute Motif-grafted hybrid polypeptides and uses thereof
DK3072978T3 (en) 2002-05-09 2018-09-17 Brigham & Womens Hospital Inc : 1L1RL-1 AS A CARDIOVASCULAR DISEASE MARKER
WO2003097872A2 (en) 2002-05-21 2003-11-27 Mtm Laboratories Ag G - protein coupled receptor marker molecules associated with colorectal lesions
EP1530723A1 (en) 2002-07-03 2005-05-18 Spinelix 3d microarray
US20040018577A1 (en) 2002-07-29 2004-01-29 Emerson Campbell John Lewis Multiple hybrid immunoassay
JP5179011B2 (ja) 2002-10-09 2013-04-10 ディーエムアイ バイオサイエンシズ インコーポレイテッド 胎盤虚血および多臓器不全のモニタリング
US7135329B2 (en) 2002-11-18 2006-11-14 Princeton Biomeditech Corporation Immunoassay device for diagnosing congestive heart failure and predicting mortality in congestive heart failure patients
EP1620567A1 (en) 2003-04-15 2006-02-01 Hans-Jürgen Thiesen Method for diagnosing rheumatoid arthritis or osteoarthritis
FI20030652A0 (fi) 2003-04-30 2003-04-30 Susann Eriksson Parannettu immunomääritys
US7659062B2 (en) 2003-06-03 2010-02-09 The Board of Trustee of the University of Arkansas System Gene expression profiling of uterine serous papillary carcinomas and ovarian serous papillary tumors
US7927795B2 (en) 2003-06-09 2011-04-19 Board Of Trustees Of The University Of Arkansas Gene expression profiling in primary ovarian serous papillary tumors and normal ovarian epithelium
AU2004260083B2 (en) 2003-07-17 2011-04-07 Pacific Edge Limited Markers for detection of gastric cancer
WO2005024603A2 (en) 2003-09-10 2005-03-17 The Board Of Regents Of The University Of Texas System Methods for detecting, diagnosing and treating human renal cell carcinoma
US7634360B2 (en) 2003-09-23 2009-12-15 Prediction Sciences, LL Cellular fibronectin as a diagnostic marker in stroke and methods of use thereof
US7392140B2 (en) 2003-09-23 2008-06-24 Prediction Sciences, Llc Cellular fibronectin as a diagnostic marker in stroke and methods of use thereof
US20080010024A1 (en) 2003-09-23 2008-01-10 Prediction Sciences Llp Cellular fibronectin as a diagnostic marker in cardiovascular disease and methods of use thereof
US20050181386A1 (en) 2003-09-23 2005-08-18 Cornelius Diamond Diagnostic markers of cardiovascular illness and methods of use thereof
US20050164238A1 (en) 2003-09-29 2005-07-28 Biosite, Inc. Methods and compositions for the diagnosis of sepsis
US20050148029A1 (en) 2003-09-29 2005-07-07 Biosite, Inc. Methods and compositions for determining treatment regimens in systemic inflammatory response syndromes
DE10349124A1 (de) 2003-10-22 2005-05-19 Roche Diagnostics Gmbh Differenzialdiagnostik mit Hepcidin
US20050239706A1 (en) 2003-10-31 2005-10-27 Washington University In St. Louis Modulation of fiaf and the gastrointestinal microbiota as a means to control energy storage in a subject
EP1530047A1 (en) 2003-11-07 2005-05-11 Roche Diagnostics GmbH Proximal markers of arterial thrombosis and inflammation for risk stratification of coronary heart disease
US7598049B2 (en) 2003-11-19 2009-10-06 Satoris, Inc. Methods for diagnosis of Alzheimer's Disease in blood samples
US20050164409A1 (en) 2003-12-10 2005-07-28 Kiernan Urban A. Method and apparatus for mass spectrometric immunoassay analysis of specific biological fluid proteins
WO2005070086A2 (en) 2004-01-21 2005-08-04 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for determining a graft tolerant phenotype in a subject
JP4912894B2 (ja) 2004-02-19 2012-04-11 イェール ユニバーシティー プロテオーム技術を使用した癌タンパク質バイオマーカーの同定
ES2636470T3 (es) 2004-04-09 2017-10-05 Genomic Health, Inc. Marcadores de expresión génica para predecir la respuesta a la quimioterapia
US20050260153A1 (en) 2004-04-13 2005-11-24 Pericles Calias Facilitation of iontophoresis using charged moieties
ES2367311T3 (es) 2004-04-15 2011-11-02 University Of Florida Research Foundation, Inc. Productos de degradación proteolítica de map-2 como biomarcadores de diagnóstico para las lesiones neurales.
DK1745287T3 (da) 2004-05-11 2011-01-24 Univ Pittsburgh Diagnostisering og monitorering af inflammatoriske sygdomme ved at måle komplementkomponenter på hvide blodlegemer
US20060039863A1 (en) 2004-07-22 2006-02-23 Michael Schirner Use of cyanine dyes for the diagnosis of disease associated with angiogenesis
US20060105419A1 (en) 2004-08-16 2006-05-18 Biosite, Inc. Use of a glutathione peroxidase 1 as a marker in cardiovascular conditions
US20080090759A1 (en) 2004-08-30 2008-04-17 Robert Kokenyesi Methods and kits for predicting risk for preterm labor
WO2006069073A2 (en) 2004-12-20 2006-06-29 The General Hospital Corporation Use of angiopoietins in anti-tumor therapy
US20060134698A1 (en) 2004-12-20 2006-06-22 Evanston Northwestern Healthcare Research Institute Methods for treating cardiac disease by modifying an N-terminal domain of troponin I
CA2592527A1 (en) 2004-12-27 2006-07-06 National University Corporation Okayama University Method of examining pregnancy toxemia
WO2006074367A2 (en) 2005-01-05 2006-07-13 Sloan-Kettering Institute For Cancer Research Method of predicting and reducing risk of metastasis of breast cancer to lung
WO2006094185A2 (en) 2005-03-03 2006-09-08 Dmi Biosciences Inc. Quantification of proteins
CN101185000A (zh) 2005-03-29 2008-05-21 因弗因斯医药瑞士股份有限公司 监测患者的方法和装置
US7776550B2 (en) 2005-05-05 2010-08-17 Philadelphia Health & Education Corporation Diagnosis of liver pathology through assessment of protein glycosylation
GB0509305D0 (en) 2005-05-06 2005-06-15 Randox Lab Ltd Method
US20060275849A1 (en) 2005-06-07 2006-12-07 Beckman Coulter, Inc. Monoclonal antibody reagents
JP4800384B2 (ja) 2005-06-08 2011-10-26 ヒタチ ケミカル リサーチ センター インコーポレイテッド 腫瘍細胞及び刺激された白血球におけるｍＲＮＡの発現プロファイルに基づく腫瘍性疾患に対する免疫応答を予測する方法
CA2610910A1 (en) 2005-06-09 2006-12-21 Paul H. Mcpherson Methods and compositions for the diagnosis of venous thromboembolic disease
US20070099239A1 (en) 2005-06-24 2007-05-03 Raymond Tabibiazar Methods and compositions for diagnosis and monitoring of atherosclerotic cardiovascular disease
US7785865B2 (en) 2005-06-28 2010-08-31 Zbx Corporation Membrane array and analytical device
WO2007028070A2 (en) 2005-08-30 2007-03-08 Biosite, Inc. Use of soluble flt-1 and its fragments in cardiovascular conditions
US20070154482A1 (en) 2005-09-12 2007-07-05 Beth Israel Deaconess Medical Center Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
AU2006299417A1 (en) 2005-10-03 2007-04-12 Biosite Incorporated Methods and compositions for diagnosis and/or prognosis in Systemic Inflammatory Response Syndromes
US7947437B2 (en) 2005-10-17 2011-05-24 Sword Diagnostics, Inc. Methods for detecting organisms and enzymatic reactions using raman spectroscopy
US7766829B2 (en) 2005-11-04 2010-08-03 Abbott Diabetes Care Inc. Method and system for providing basal profile modification in analyte monitoring and management systems
KR20080084806A (ko) 2005-11-10 2008-09-19 시너젠즈 바이오사이언스 리미티드 심혈관 기능 및 질환의 평가를 위한 방법 및 조성물
US7908090B2 (en) 2005-11-30 2011-03-15 The Board Of Trustees Of The Leland Stanford Junior University Signatures for human aging
US20140273007A1 (en) 2013-03-12 2014-09-18 Dr. Susan Love Research Foundation Devices and methods for screening nipple aspirate for markers indicative of risk of developing breast cancer
US20070134814A1 (en) 2005-12-09 2007-06-14 Kajander E O Methods and compositions for the detection of calcifying nano-particles, identification and quantification of associated proteins thereon, and correlation to disease
WO2007070021A1 (en) 2005-12-09 2007-06-21 Nanobac Pharmaceuticals Incorporated Detection of calcifying nano-particles, and associated proteins thereon
US7790463B2 (en) 2006-02-02 2010-09-07 Yale University Methods of determining whether a pregnant woman is at risk of developing preeclampsia
NZ571791A (en) 2006-03-08 2012-03-30 Archemix Llc Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders
WO2007103568A2 (en) 2006-03-09 2007-09-13 Biosite, Inc. Methods and compositions for the diagnosis of diseases of the aorta
AU2007227251A1 (en) 2006-03-20 2007-09-27 Amgen Fremont, Inc. Antibodies directed to angiopoietin-like protein 4 and uses thereof
JP5308328B2 (ja) 2006-04-04 2013-10-09 シングレックス，インコーポレイテッド トロポニンの分析のための高感度のシステムおよび方法
US7838250B1 (en) 2006-04-04 2010-11-23 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
DK2848938T3 (da) 2006-04-24 2017-11-13 Critical Care Diagnostics Inc Evaluering af effektiviteten af en behandling hos et individ baseret på st2- niveauer
US20100055730A1 (en) 2006-05-05 2010-03-04 Anny Usheva-Simidjiyska Methods for the Diagnosis and Treatment of Female Infertility Using Molecular Markers
EP2021512A4 (en) 2006-05-08 2009-08-05 Tethys Bioscience Inc SYSTEMS AND METHODS FOR DEVELOPING DIAGNOSTIC TESTS BASED ON BIOMARKER INFORMATION FROM EXISTING CLINICAL SAMPLE ASSEMBLIES
US20080118924A1 (en) 2006-05-26 2008-05-22 Buechler Kenneth F Use of natriuretic peptides as diagnostic and prognostic indicators in vascular diseases
JP5097206B2 (ja) 2006-07-28 2012-12-12 エイディーライフ インコーポレイティッド 診断および治療のためのペプチドプローブ
EP1887361A1 (en) 2006-08-07 2008-02-13 Bio-Rad Pasteur Method for the prediction of vascular events
EP2469282A1 (en) 2006-09-08 2012-06-27 University of Oxford Clinical diagnosis of hepatic fibrosis using a novel panel of human serum protein biomarkers
WO2008034016A2 (en) 2006-09-15 2008-03-20 Foldrx Pharmaceuticals, Inc. Assays for detecting native-state proteins and identifying compounds that modulate the stability of native-state proteins
US20100196880A1 (en) 2006-10-06 2010-08-05 Ebenezer Satyaraj Compositions and multiplex assays for measuring biological mediators of physiological health
US7776605B2 (en) 2006-10-26 2010-08-17 Abbott Laboratories Assay for cardiac troponin autoantibodies
US20080305512A1 (en) 2006-10-26 2008-12-11 Mattingly Phillip G Assay for cardiac troponin autoantibodies
JP2010513277A (ja) * 2006-12-13 2010-04-30 ギリード・サイエンシズ・インコーポレーテッド ＣＯＰＤおよび慢性気管支炎の治療のためのムスカリン受容体アンタゴニストおよびβ−アゴニストの共通プロドラッグとしてのモノホスフェート
WO2008079269A2 (en) * 2006-12-19 2008-07-03 Genego, Inc. Novel methods for functional analysis of high-throughput experimental data and gene groups identified therfrom
EP2129795A4 (en) 2006-12-19 2010-10-20 Synergenz Bioscience Ltd METHODS AND COMPOSITIONS FOR ASSESSING FUNCTION AND CARDIOVASCULAR DISORDERS
CA2670516A1 (en) 2006-12-20 2008-06-26 Antibodyshop A/S Assessment of patients with sepsis to determine a requirement for therapeutic intervention with an antiinflammatory and/or anticoagulatory agent
CA2710286A1 (en) 2006-12-22 2008-07-03 Aviir, Inc. Two biomarkers for diagnosis and monitoring of atherosclerotic cardiovascular disease
US7855054B2 (en) 2007-01-16 2010-12-21 Somalogic, Inc. Multiplexed analyses of test samples
US7947447B2 (en) 2007-01-16 2011-05-24 Somalogic, Inc. Method for generating aptamers with improved off-rates
US20080300798A1 (en) 2007-04-16 2008-12-04 Mcdevitt John T Cardibioindex/cardibioscore and utility of salivary proteome in cardiovascular diagnostics
US7901888B2 (en) 2007-05-09 2011-03-08 The Regents Of The University Of California Multigene diagnostic assay for malignant thyroid neoplasm
BRPI0810631A2 (pt) 2007-05-10 2017-05-09 Acorda Therapeutics Inc métodos para detecção de dano cardíaco
CN101802225B (zh) 2007-07-17 2013-10-30 私募蛋白质体公司 检测样品的多元分析
EP2019318A1 (en) 2007-07-27 2009-01-28 Erasmus University Medical Center Rotterdam Protein markers for cardiovascular events
WO2010012509A1 (en) 2008-08-01 2010-02-04 Bio-Rad Pasteur Method for the in vitro diagnosis of stroke
US7888051B2 (en) 2007-09-11 2011-02-15 Cancer Prevention And Cure, Ltd. Method of identifying biomarkers in human serum indicative of pathologies of human lung tissues
EP2220115A2 (en) 2007-12-13 2010-08-25 Glaxo Group Limited Polypeptides, antibody variable domains & antagonists
GB0724735D0 (en) 2007-12-19 2008-01-30 Psynova Neurotech Ltd Methods and biomarkers for diagnosing and monitoring psychotic disorders
WO2009097584A1 (en) 2008-01-30 2009-08-06 Proteogenix, Inc. Maternal serum biomarkers for detection of pre-eclampsia
US20090299155A1 (en) 2008-01-30 2009-12-03 Dexcom, Inc. Continuous cardiac marker sensor system
WO2009108073A1 (en) 2008-02-28 2009-09-03 Auckland Uniservices Limited Biomarkers for prediction of preeclampsia and/or cardiovascular disease
CA2716522A1 (en) 2008-03-05 2009-10-15 Singulex, Inc. Methods and compositions for highly sensitive detection of molecules
WO2009111033A2 (en) 2008-03-05 2009-09-11 Axela Inc. Detection of biomarkers and biomarker complexes
WO2009118185A1 (en) 2008-03-27 2009-10-01 Universitätsklinikum Heidelberg Peptides derived from cardial troponin i and their use as prognostic and diagnostic markers for heart failure
JP5526122B2 (ja) 2008-04-18 2014-06-18 クリティカル ケア ダイアグノスティクス インコーポレイテッド 主要有害心イベントのリスクを予測する方法
FR2934767B1 (fr) 2008-08-06 2011-11-25 Assist Publ Hopitaux De Paris Nouveau procede de pronostic associe aux cas d'hemorragies post-partum.
GB0818660D0 (en) 2008-10-10 2008-11-19 Cambridge Entpr Ltd Biomarkers
US20110295782A1 (en) 2008-10-15 2011-12-01 Alexander Stojadinovic Clinical Decision Model
JP5439494B2 (ja) 2008-10-21 2014-03-12 バイエル ヘルスケア エルエルシー 肝細胞癌と関連するシグネチャ遺伝子の同定
US20110257140A1 (en) 2008-10-24 2011-10-20 Inserm (Institut National De La Sante Et De La Rec Herche Medicale) Biomarkers of Mineralocorticoid Receptor Activation
EP2382466B1 (en) 2008-12-30 2016-03-09 Children's Medical Center Corporation Method of predicting acute appendicitis
WO2010078443A1 (en) 2008-12-31 2010-07-08 Abbott Point Of Care Inc. Method and device for immunoassay using nucleotide conjugates
CA2751090A1 (en) 2009-01-30 2010-08-05 Electrophoretics Limited Method for the in vitro diagnosis of stroke
US20100216256A1 (en) 2009-02-17 2010-08-26 Florida State University Research Foundation Nanobelt-based sensors and detection methods
JP5384672B2 (ja) * 2009-02-24 2014-01-08 エフ．ホフマン−ラ ロシュ アーゲー 癌のマーカーとしてのｓ−ＥｒｂＢ−３の使用
WO2010129302A1 (en) 2009-04-28 2010-11-11 Innovative Laboratory Technologies, Inc. Lateral-flow immuno-chromatographic assay devices
WO2010144358A1 (en) 2009-06-08 2010-12-16 Singulex, Inc. Highly sensitive biomarker panels
WO2010144553A2 (en) 2009-06-10 2010-12-16 Tufts Medical Center, Inc. Methods for diagnosing blood vessel reocclusion
WO2011017077A2 (en) 2009-07-27 2011-02-10 Trustees Of Boston University Nanochannel-based sensor system with controlled sensitivity
EP2467720A1 (en) 2009-08-20 2012-06-27 The Board of Regents of The University of Texas System Methods and compositions for diagnosis of acute myocardial infarction (ami)
CA2772014A1 (en) 2009-08-31 2011-03-03 Abbott Laboratories Biomarkers for prediction of major adverse cardiac events and uses thereof
CN102597774B (zh) 2009-09-23 2015-05-13 皇家飞利浦电子股份有限公司 利用多种磁性标记示踪结合试剂的结合测定
US8846414B2 (en) 2009-09-29 2014-09-30 Advanced Liquid Logic, Inc. Detection of cardiac markers on a droplet actuator
US20120231472A1 (en) 2009-11-07 2012-09-13 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2504455A4 (en) 2009-11-24 2013-05-22 Commw Scient Ind Res Org METHODS, KITS AND REAGENTS FOR DIAGNOSIS, DIAGNOSTIC SUPPORT AND / OR MONITORING THE PROGRESS OF A NEUROLOGICAL SENSE
US8652788B2 (en) 2009-12-02 2014-02-18 Abbott Laboratories Assay for diagnosis of cardiac myocyte damage
US20110136141A1 (en) 2009-12-03 2011-06-09 Abbott Laboratories Peptide reagents and method for inhibiting autoantibody antigen binding
EP2517015A1 (en) 2009-12-23 2012-10-31 Koninklijke Philips Electronics N.V. Analyte measurement apparatus and method
JP5732474B2 (ja) 2010-01-08 2015-06-10 カヴァディス・ベスローテン・フェンノートシャップ 心血管系イベントを予測するためのエキソソームバイオマーカーの決定
US20130023473A1 (en) 2010-01-20 2013-01-24 Stephane Germain Methods and pharmaceutical composition for the preservation of vascular endothelial cell barrier integrity
EP2531622B1 (en) 2010-02-05 2016-04-06 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2011103330A2 (en) 2010-02-17 2011-08-25 The Johns Hopkins University Novel phosphorylation of cardiac troponin i as a monitor for cardiac injury
EP2553117A1 (en) 2010-03-28 2013-02-06 Sword Diagnostics, Inc. Methods for detecting raman scattering using aromatic compounds comprising phosphate and at least one non-laser light source
EP2372364A1 (en) 2010-03-31 2011-10-05 Medizinische Hochschule Hannover Biomarker for pulmonary hypertension
AU2011249908A1 (en) 2010-05-06 2012-11-22 Singulex, Inc. Methods for diagnosing, staging, predicting risk for developing and identifying treatment responders for rheumatoid arthritis
WO2011143574A2 (en) 2010-05-14 2011-11-17 The Trustees Of The University Of Pennsylvania Plasma biomarkers for diagnosis of alzheimer's disease
EP2899545B1 (en) 2010-06-23 2018-08-22 Astute Medical, Inc. Methods for diagnosis and prognosis of renal injury and renal failure
US9918656B2 (en) 2010-06-25 2018-03-20 Massachusetts Institute Of Technology Implantable magnetic relaxation sensors and methods of measuring a sensor's cumulative exposure to a biomarker
ES2387292B1 (es) 2010-06-29 2013-10-30 Fundacio Institut De Recerca Hospital Universitari Vall D'hebron Combinacion de snps para determinar el riesgo de sufrir una enfermedad neurovascular
SG186953A1 (en) 2010-07-09 2013-02-28 Somalogic Inc Lung cancer biomarkers and uses thereof
CA2804763C (en) * 2010-07-14 2023-01-03 The Regents Of The University Of California Biomarkers for diagnosis of transient ischemic attacks
US20120142632A1 (en) 2010-08-04 2012-06-07 St. Vincent's Institute Of Medical Research Diagnostic and prognostic assay
CN103118785B (zh) 2010-08-05 2015-11-25 雅培医护站股份有限公司 使用易感磁微珠捕获的免疫测定方法和装置
WO2012019109A1 (en) 2010-08-05 2012-02-09 Abbott Point Of Care Inc. Oscillating immunoassay method and device
CN106011233A (zh) * 2010-08-13 2016-10-12 莫尔豪斯医学院 中风的生物标记
CN108387744A (zh) 2010-08-26 2018-08-10 弗·哈夫曼-拉罗切有限公司 生物标志物在评估从动脉高血压向心力衰竭的早期转变中的用途
CN103429753A (zh) 2010-09-27 2013-12-04 私募蛋白质体公司 间皮瘤生物标记及其用途
WO2012052757A1 (en) 2010-10-20 2012-04-26 Astrazeneca Ab Tumour phenotype patient selection method
US20120115175A1 (en) 2010-11-05 2012-05-10 Tufts Medical Center, Inc. Methods for diagnosing elevated right or left ventricular filling pressure
EP2638401B1 (en) 2010-11-12 2017-02-15 The Johns Hopkins University Citrullinated proteins: a post-translated modification of myocardial proteins as marker of physiological and pathological disease
CA2824434A1 (en) 2011-01-08 2012-07-12 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP2014505259A (ja) 2011-02-03 2014-02-27 アボット・ラボラトリーズ 慢性心不全における予後診断および診断の方法
US20140024046A1 (en) 2011-02-18 2014-01-23 Cavadis B.V. Exosomal Biomarkers for Cardiovasular Events
EP2678448A4 (en) * 2011-02-22 2014-10-01 Caris Life Sciences Luxembourg Holdings S A R L CIRCULATING BIOMARKERS
WO2012122374A2 (en) 2011-03-08 2012-09-13 Children's Medical Center Corporation Non-invasive methods for diagnosing chronic organ transplant rejection
FI20115367A0 (fi) 2011-04-15 2011-04-15 Hytest Oy Menetelmä sydän- ja verisuonitapahtumien määrittämiseksi käyttämällä IGFBP-fragmentteja
AU2012249288C1 (en) 2011-04-29 2017-12-21 Lung Cancer Proteomics Llc Methods of identification and diagnosis of lung diseases using classification systems and kits thereof
EP2532748B1 (en) 2011-06-07 2014-10-08 Postech Academy-industry Foundation DNA aptamer specifically binding to human cardiac troponin I
US9387236B2 (en) 2011-06-10 2016-07-12 Prothera Inc. Pharmaceutical compositions containing protease and methods for the treatment of lysosomal storage diseases
CA2842072A1 (en) 2011-07-18 2013-01-24 James V. Snider Methods of treating cardiovascular diseases and predicting the efficacy of exercise therapy
CN103782177B (zh) 2011-08-08 2017-10-03 南洋理工大学 血管生成素样4及其在调节细胞渗漏中的用途
KR20140067001A (ko) * 2011-08-08 2014-06-03 카리스 라이프 사이언스 룩셈부르크 홀딩스, 에스.에이.알.엘. 생물지표 조성물 및 방법
CN103917638A (zh) 2011-09-08 2014-07-09 Nexusdx股份有限公司 多级分析物检定
EP2594940A1 (en) 2011-11-16 2013-05-22 Koninklijke Philips Electronics N.V. Particle repulsion to enhance surface contact in magnetic particle immunoassays
EP2594942A1 (en) 2011-11-16 2013-05-22 Koninklijke Philips Electronics N.V. Long rigid spacers to enhance binding kinetics in immunoassays
WO2013085367A1 (en) 2011-12-09 2013-06-13 Kyungpook National University Industry-Academic Cooperation Foundation Cardiac troponin i-targeting peptide and use thereof
US8986530B2 (en) 2012-01-09 2015-03-24 Washington State University Sample analysis systems, devices, and associated methods of operation
US9140695B2 (en) 2012-01-18 2015-09-22 University Of Utah Research Foundation Methods for analysis of free and autoantibody-bound biomarkers and associated compositions, devices, and systems
EP2820427A4 (en) 2012-02-27 2015-12-02 Univ Health Network Uhn BIOMARKER FOR THE EARLY RECOGNITION OF A CRITICAL OR LIVELY RESPONSE TO A DISEASE AND FOR MONITORING THE RESPONSE TO THE TREATMENT
EP2825665B1 (en) * 2012-03-14 2017-09-06 Ruprecht-Karls-Universität Heidelberg Epigenetic signatures as marker for cardiomyopathies and myocardial insufficiencies
CN104755930B (zh) 2012-03-26 2018-02-09 埃克塞尔柯尔有限责任公司 用于检测分析物的装置和方法
EP2834638B1 (en) 2012-04-02 2020-02-12 Astute Medical, Inc. Methods for diagnosis and prognosis of sepsis
CA2870810A1 (en) 2012-04-18 2013-10-24 The University Of British Columiba Biomarkers for recovered heart function
WO2013163345A1 (en) 2012-04-24 2013-10-31 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of stroke or other cerebral injury
WO2013162368A1 (en) 2012-04-26 2013-10-31 Stichting Vu-Vumc Biomarkers
WO2013169890A1 (en) 2012-05-08 2013-11-14 Bg Medicine, Inc. Systems and methods for assessing disease risk, status, and prognosis
ITMI20120865A1 (it) 2012-05-18 2013-11-19 Antonio Bertolotto Biomarcatori per patologie del sistema nervoso centrale
EP3434260A1 (en) 2012-05-18 2019-01-30 Critical Care Diagnostics, Inc. Methods for treating or predicting risk of ventricular tachyarrhythmia event
US9482616B2 (en) 2012-06-06 2016-11-01 Board of Regents of the Nevada System of Higher Education, on behalf the University of Nevada, Reno Methods, kits and systems for signal amplification for bioassays using zinc nanoparticles
US10175250B2 (en) 2012-06-11 2019-01-08 Gabriela Venturini Da Silva Nitrated cardiac troponin I as a biomarker of cardiac ischemia
WO2014004889A2 (en) 2012-06-27 2014-01-03 Musc Foundation For Research Development Plasma analytes predict diagnosis and prognosis of thoracic aortic aneurysm
DK2885641T3 (da) 2012-08-16 2018-01-29 Critical Care Diagnostics Inc Fremgangsmådeer til forudsigelse af risiko for udvikling af hypertension
US20140120551A1 (en) 2012-10-29 2014-05-01 Academia Sinica Methods of diagnosing, predicting and treating cardiovascular disease
EP2932696A4 (en) 2012-12-12 2016-08-24 Green Domain Design Llc ASSAY DEVICE
US20140206632A1 (en) 2013-01-22 2014-07-24 Singulex, Inc. Endothelin in the Diagnosis of Cardiac Disease
EP2953524B1 (en) 2013-02-06 2018-08-01 Freenome Holdings Inc. Systems and methods for early disease detection and real-time disease monitoring
US20140227715A1 (en) 2013-02-14 2014-08-14 Singulex, Inc. Non-Invasive methods to Determine Vulnerable Plaque Burden in Subjects
WO2014144605A1 (en) 2013-03-15 2014-09-18 Myriad Genetics, Inc. Biomarkers for major depressive disorder
WO2014187884A2 (en) 2013-05-22 2014-11-27 Comprehensive Biomarker Center Gmbh Mirnas as non-invasive biomarkers for heart failure
EP3041514B1 (en) 2013-09-03 2019-11-13 Mayo Foundation for Medical Education and Research Reducing the risk of major adverse cardiac events
GB201315943D0 (en) 2013-09-06 2013-10-23 Randox Lab Ltd Risk stratification of suspected ami patients
GB2518221A (en) 2013-09-16 2015-03-18 Sergej Michailovic Kiprijanov Tetravalent antigen-binding protein molecule
EP3047270A4 (en) 2013-09-20 2017-07-19 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of appendicitis and differentiation of causes of abdominal pain
EP3052936A4 (en) 2013-09-23 2017-05-24 Assaypro, LLC Immunoassays using over-labeled fluorescent probes
GB2519786A (en) 2013-10-30 2015-05-06 Sergej Michailovic Kiprijanov Multivalent antigen-binding protein molecules
WO2015073396A1 (en) * 2013-11-12 2015-05-21 The Brigham And Women's Hospital, Inc. Growth differentiation factor (gdf) for treatment of diastolic heart failure
WO2015073710A2 (en) * 2013-11-14 2015-05-21 THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTEMENT OF HEALTH AND HUMAN SERVICES Detection of atherosclerotic cardiovascular disease risk and myocardial infarction risk
WO2015085368A1 (en) 2013-12-10 2015-06-18 The University Of Queensland Kits and methods for the diagnosis, treatment, prevention and monitoring of diabetes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110144914A1 (en) * 2009-12-09 2011-06-16 Doug Harrington Biomarker assay for diagnosis and classification of cardiovascular disease
JP2013513387A (ja) * 2009-12-09 2013-04-22 アヴィール インコーポレイテッド 循環器疾患の診断と分類のためのバイオマーカーアッセイ
WO2013049674A1 (en) * 2011-09-30 2013-04-04 Somalogic, Inc. Cardiovascular risk event prediction and uses thereof

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021507216A (ja) * 2017-12-13 2021-02-22 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 脳卒中の予測のための循環アンジオポエチン−２（Ａｎｇ−２）およびインスリン様増殖因子結合タンパク質７（ＩＧＦＢＰ７）
JP7058331B2 (ja) 2017-12-13 2022-04-21 エフ．ホフマン－ラ ロシュ アーゲー 脳卒中の予測のための循環アンジオポエチン－２（Ａｎｇ－２）およびインスリン様増殖因子結合タンパク質７（ＩＧＦＢＰ７）
US11946938B2 (en) 2017-12-13 2024-04-02 Roche Diagnostics Operations, Inc. Circulating Angiopoietin-2 (Ang-2) and insulin-like growth factor-binding protein 7 (IGFBP7) for the prediction of stroke
JP2022546515A (ja) * 2019-09-03 2022-11-04 ソマロジック オペレーティング カンパニー インコーポレイテッド 心血管リスク／イベントの予測及びその使用
JP7712913B2 (ja) 2019-09-03 2025-07-24 ソマロジック オペレーティング カンパニー インコーポレイテッド 心血管リスク／イベントの予測及びその使用
JP2023502984A (ja) * 2019-11-15 2023-01-26 ゲイシンガー クリニック ヘルスケア集団の管理に対する機械学習手法のためのシステムおよび方法
JP7700114B2 (ja) 2019-11-15 2025-06-30 ゲイシンガー クリニック ヘルスケア集団の管理に対する機械学習手法のためのシステムおよび方法
JP2023546563A (ja) * 2020-10-20 2023-11-06 ソマロジック オペレーティング カンパニー インコーポレイテッド 心血管イベントリスクの予測
JP2024525146A (ja) * 2021-06-15 2024-07-10 ソマロジック オペレーティング カンパニー インコーポレイテッド 腎不全の予測及びその使用

Also Published As

Publication number Publication date
US20180188267A1 (en) 2018-07-05
US10670611B2 (en) 2020-06-02
AU2014407088B2 (en) 2021-09-23
CA2961340A1 (en) 2016-03-31
JP2019207249A (ja) 2019-12-05
ES2792227T3 (es) 2020-11-10
JP6956762B2 (ja) 2021-11-02
BR112017005730B1 (pt) 2023-12-12
JP7270696B2 (ja) 2023-05-10
CA3103560C (en) 2023-01-17
WO2016048388A1 (en) 2016-03-31
EP3198023B1 (en) 2020-04-22
BR112017005730A8 (pt) 2022-10-18
KR20170062453A (ko) 2017-06-07
US20160091499A1 (en) 2016-03-31
EP3198023A1 (en) 2017-08-02
AU2014407088A1 (en) 2017-03-16
BR112017005730A2 (pt) 2017-12-19
CA2961340C (en) 2023-10-17
KR102328327B1 (ko) 2021-11-22
JP2022008847A (ja) 2022-01-14
CA3103560A1 (en) 2016-03-31

Similar Documents

Publication Publication Date Title
JP7270696B2 (ja) 心血管系のリスクイベントの予測及びその使用
JP6917432B2 (ja) 心血管系リスクイベントの予測およびその使用
JP2025118715A (ja) 心血管リスク／イベントの予測及びその使用
US20230393146A1 (en) Cardiovascular Event Risk Prediction
HK40129964A (en) Cardiovascular event risk prediction
HK40095601A (zh) 心血管事件风险预测
HK40078070B (zh) 心血管风险事件预测及其用途
CA3161906A1 (en) Methods of determining impaired glucose tolerance
HK1234105B (en) Cardiovascular risk event prediction and uses thereof
HK1234105A1 (en) Cardiovascular risk event prediction and uses thereof

Legal Events

Date Code Title Description
A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A80

Effective date: 20170420

Free format text: JAPANESE INTERMEDIATE CODE: A801

Effective date: 20170323

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171026

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171026

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180731

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180731

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181025

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190402